Details of Disease

General Information of Disease (ID: DISWVVDR)

Disease Name Transitional cell carcinoma
Synonyms
transitional cell neoplasm; transitional cell tumour; transitional cell tumor; carcinoma of transitional epithelial cell; urothelial cell carcinoma; carcinoma of urothelial cell; transitional epithelial cell carcinoma; carcinoma, urothelial, malignant; transitional carcinoma; transitional cell carcinoma
Definition
A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.
Disease Hierarchy
DISH9F1N: Carcinoma
DISWVVDR: Transitional cell carcinoma
Disease Identifiers
MONDO ID
MONDO_0006474
MESH ID
D002295
UMLS CUI
C0007138
MedGen ID
2875
SNOMED CT ID
27090000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Atezolizumab DMMF8U0 Approved Monoclonal antibody [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 73 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CREBBP TTFRCTK Limited Biomarker [2]
EP300 TTGH73N Limited Biomarker [3]
GGH TTZJRL0 Limited Biomarker [4]
KCNN3 TT9JH25 Limited Biomarker [5]
KMT2A TT1GNDM Limited Biomarker [3]
PABPC1 TTHC8EF Limited Biomarker [6]
PTGS2 TTVKILB Limited Altered Expression [7]
TACC3 TTQ4UFD Limited Biomarker [8]
PLAU TTGY7WI Disputed Altered Expression [9]
BCL6 TTC9YX5 moderate Genetic Variation [10]
CDKN1A TT9GUW0 moderate Biomarker [11]
GRIK2 TT0K5RG moderate Biomarker [12]
LTB4R TTN53ZF moderate Altered Expression [13]
LTB4R2 TTVJX54 moderate Altered Expression [13]
PRAME TTPH7T0 moderate Altered Expression [14]
ANXA1 TTUCK4B Strong ModifyingMutation [15]
ANXA10 TT0NL6U Strong Biomarker [16]
APOA1 TT5S8DR Strong Biomarker [17]
BSG TT5UJWD Strong Biomarker [18]
BST2 TT90BJT Strong Biomarker [19]
CASP4 TT6KIOT Strong Biomarker [20]
CBX7 TTBN3HC Strong Biomarker [21]
CCNA2 TTAMQ62 Strong Altered Expression [22]
CCNE1 TTCEJ4F Strong Biomarker [23]
CD3E TTZAT79 Strong Altered Expression [24]
CDC20 TTBKFDV Strong Altered Expression [25]
CSF3 TT5TQ2W Strong Therapeutic [26]
CTAG1A TTE5ITK Strong Altered Expression [27]
DEPDC1 TT8S9CM Strong Biomarker [28]
EIF5A2 TTH53G9 Strong Biomarker [29]
ESR2 TTOM3J0 Strong Altered Expression [30]
FABP2 TTS4YLO Strong Biomarker [31]
FGFR3 TTST7KB Strong Genetic Variation [32]
GFRA3 TT63XRS Strong Altered Expression [33]
GPR87 TTO897C Strong Biomarker [34]
GPX1 TTYAHBP Strong Biomarker [35]
GSTA1 TT4P8DE Strong Biomarker [36]
HDAC8 TTT6LFV Strong Biomarker [37]
HOXB13 TTZ6I58 Strong Biomarker [38]
HRAS TT28ZON Strong Biomarker [39]
HRH2 TTQHJ1K Strong Biomarker [40]
IFNA2 TTSIUJ9 Strong Therapeutic [41]
IFNB1 TT4TZ8J Strong Therapeutic [42]
IGFBP3 TTZHNQA Strong Biomarker [43]
IMP3 TTEJA2R Strong Altered Expression [44]
INHBA TTVB30D Strong Altered Expression [45]
KIF20B TTQECT2 Strong Biomarker [28]
KRT17 TTKV0EC Strong Biomarker [46]
LASP1 TTZJA87 Strong Biomarker [47]
MAGEA4 TT9EQUY Strong Altered Expression [48]
MAGEC2 TTKGUEB Strong Altered Expression [14]
MKI67 TTB4UNG Strong Biomarker [49]
MLH1 TTISG27 Strong Biomarker [50]
MSH2 TTCAWRT Strong Biomarker [50]
NACC1 TT4AQ5F Strong Altered Expression [51]
NCOA3 TT124R0 Strong Altered Expression [52]
NECTIN4 TTPO9EG Strong Biomarker [53]
PDCD1LG2 TTW14O3 Strong Biomarker [54]
PIKFYVE TTA4M1N Strong Biomarker [55]
PLA2G4A TTT1JVS Strong Altered Expression [56]
PSCA TT9T4AV Strong Altered Expression [57]
PTGES TTYLQ8V Strong Biomarker [58]
RECK TTRZBW7 Strong Altered Expression [59]
RPE65 TTBOH16 Strong Altered Expression [60]
SLITRK6 TTTVEKI Strong Biomarker [53]
TLR6 TTWRI8V Strong Altered Expression [61]
TMSB4X TTMVAIU Strong Biomarker [62]
TNKS TTVUSO7 Strong Altered Expression [63]
TRPV2 TTBECWA Strong Altered Expression [64]
VDR TTK59TV Strong Biomarker [65]
DDR2 TTU98HG Definitive Altered Expression [66]
PINX1 TT4FJ3A Definitive Biomarker [67]
RSF1 TTMP86V Definitive Biomarker [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 73 DTT(s)
This Disease Is Related to 4 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP2A13 DEXZA9U Strong Genetic Variation [69]
GSTO2 DEHMPZR Strong Genetic Variation [70]
UGT2B7 DEB3CV1 Strong Genetic Variation [69]
UPP2 DEBQ2WU Strong Genetic Variation [71]
------------------------------------------------------------------------------------
This Disease Is Related to 119 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
APAF1 OTJWIVY0 Limited Posttranslational Modification [72]
CHD6 OTEHW1U2 Limited Biomarker [3]
ESPL1 OTMGEVOK Limited Biomarker [8]
KMT2C OTC59BCO Limited Biomarker [3]
KRT14 OTUVZ1DW Limited Genetic Variation [73]
NCOR1 OT04XNOU Limited Biomarker [3]
STAG2 OTR6X1Q7 Limited Genetic Variation [74]
TOMM34 OTH6MITE Limited Altered Expression [75]
NEURL1 OT2C4P70 Disputed Altered Expression [76]
DAPK1 OTNCNUCO moderate Biomarker [77]
DEDD OTIL349E moderate Biomarker [78]
NKX2-1 OTCMEJTA moderate Altered Expression [79]
SET OTGYYQJO moderate Biomarker [80]
SPARCL1 OT74DWMV moderate Posttranslational Modification [81]
TIMM8A OTDX9687 moderate Biomarker [82]
TNFAIP6 OT1SLUZH moderate Biomarker [83]
ALKBH1 OTADGU5D Strong Biomarker [84]
ALKBH2 OTSQW0BG Strong Biomarker [85]
ALKBH3 OTS1CD9Z Strong Altered Expression [86]
AMBP OTLU8GU8 Strong Therapeutic [87]
ANKRD36B OT3MW415 Strong Biomarker [88]
ARID1A OTRWDV3P Strong Biomarker [89]
ARIH1 OTO3XDR2 Strong Biomarker [90]
B3GNT2 OTE69HV8 Strong Altered Expression [91]
BOK OTDQPDIX Strong Biomarker [92]
BRINP1 OTEUVSCP Strong Genetic Variation [93]
CAGE1 OTF3HI3N Strong Biomarker [94]
CBX8 OT4U5V1T Strong Biomarker [95]
CCAR2 OTLUDG5T Strong Genetic Variation [93]
CCL28 OTY6XNQ7 Strong Biomarker [96]
CCND2 OTDULQF9 Strong Biomarker [97]
CDC42EP3 OTUZ3U9Z Strong Biomarker [98]
CEBPD OTNBIPMY Strong Biomarker [99]
CEP55 OTGSG2PA Strong Altered Expression [100]
CEP63 OTX3TTZH Strong Altered Expression [101]
CISH OT8T5NYL Strong Biomarker [102]
CKAP4 OTDUC9ME Strong Altered Expression [60]
CKS1B OTNUPLUJ Strong Biomarker [103]
CLDN5 OTUX60YO Strong Altered Expression [104]
CMAS OTFQJG3C Strong Biomarker [105]
CRLF3 OTT9TMXN Strong Altered Expression [106]
CSTF2 OTR6G4II Strong Biomarker [107]
CTAG1B OTIQGW6U Strong Altered Expression [27]
CTNNA3 OT9Z0P1E Strong Altered Expression [108]
CUL1 OTXPE1UZ Strong Altered Expression [109]
DAB2 OTRMQTMZ Strong Altered Expression [110]
DAB2IP OTF456VC Strong Altered Expression [111]
DACH2 OT33KEUZ Strong Biomarker [112]
DACT1 OT19Z704 Strong Posttranslational Modification [113]
DGCR8 OT62LXE4 Strong Biomarker [114]
DLGAP5 OTWCN39U Strong Altered Expression [115]
DOC2A OT5G9V94 Strong Altered Expression [110]
EFNA1 OTU2NUA2 Strong Biomarker [116]
EIF4G2 OTEO98CR Strong Altered Expression [101]
ELAVL3 OTI2VI8B Strong Altered Expression [117]
EMP2 OTPS2H0L Strong Biomarker [118]
EMP3 OTODMJ1D Strong Altered Expression [119]
FCGR2C OTNLMNYB Strong Biomarker [120]
FOXA1 OTEBY0TD Strong Biomarker [121]
GAB1 OTQKE6V4 Strong Biomarker [122]
GLS2 OT08MSHL Strong Altered Expression [123]
GPX2 OTXI2NTI Strong Altered Expression [124]
HAS3 OTPM8IL8 Strong Altered Expression [125]
HEPACAM OT1MJ51D Strong Biomarker [126]
IFNA17 OTHXRYG3 Strong Biomarker [127]
IFNL2 OT4BMJF7 Strong Altered Expression [128]
IRF9 OTK4MYQJ Strong Altered Expression [106]
KAT2A OTN0W2SW Strong Genetic Variation [2]
KCNK17 OTG2NEZM Strong Biomarker [129]
KDM6A OTZM3MJJ Strong Biomarker [130]
KPNA2 OTU7FOE6 Strong Altered Expression [131]
KRT20 OT4RB40L Strong Biomarker [132]
LARGE2 OT5BZS3J Strong Biomarker [133]
LGALS4 OTKQCG0H Strong Biomarker [134]
LRPAP1 OT6DVD2Q Strong Biomarker [135]
LZTS1 OTXXL864 Strong Altered Expression [136]
MAD2L1 OTXNGZCG Strong Altered Expression [25]
MCM10 OTV0O3JN Strong Biomarker [137]
MIB1 OT5C404P Strong Biomarker [138]
MMD OTB5I4OC Strong Biomarker [139]
MMUT OTBBBV70 Strong Biomarker [140]
MUC7 OTSTMP0X Strong Altered Expression [141]
NAIP OTLA925F Strong Biomarker [142]
NDN OTYBYJ82 Strong Biomarker [143]
NID2 OTHC33FF Strong Posttranslational Modification [144]
NLRP4 OT864X7M Strong Biomarker [142]
NLRP9 OTUZVWHM Strong Biomarker [142]
NME5 OTE8OLFN Strong Altered Expression [145]
NUMA1 OTTKAVG4 Strong Biomarker [146]
PIAS1 OTZVAHZI Strong Biomarker [147]
PLEK OTB73XXA Strong Genetic Variation [148]
PMAIP1 OTXEE550 Strong Genetic Variation [149]
PPL OTTM4WDO Strong Altered Expression [150]
PRRC2C OTBX3MXM Strong Altered Expression [151]
PTF1A OT7SWA57 Strong Altered Expression [106]
PTOV1 OT94WT5X Strong Altered Expression [152]
RBX1 OTYA1UIO Strong Biomarker [153]
RING1 OTCWTAX0 Strong Biomarker [154]
RIT1 OTVNOGOH Strong Biomarker [153]
RNF2 OTFPLOIN Strong Altered Expression [155]
RRM2B OTE8GBUR Strong Genetic Variation [156]
SFXN1 OTL66767 Strong Biomarker [157]
SH3BGRL3 OTKMW34I Strong Biomarker [158]
SH3GL2 OTOE443G Strong Altered Expression [159]
ST13 OTNML6UP Strong Altered Expression [106]
TARBP2 OT1QQ8H3 Strong Genetic Variation [160]
TGFBI OTR443C5 Strong Biomarker [161]
TLR10 OTQ1KVJO Strong Altered Expression [162]
TMEM67 OTME92T5 Strong Altered Expression [163]
TMOD1 OTTRYF9Y Strong Altered Expression [164]
TMOD2 OTTTUH2W Strong Altered Expression [164]
TMOD3 OTQPNSTH Strong Altered Expression [164]
TMX1 OTX4FHYQ Strong Biomarker [165]
TNFAIP2 OTRZH80H Strong Altered Expression [166]
FLOT1 OT0JPPJZ Definitive Biomarker [167]
MRPL28 OT4LUTZU Definitive Altered Expression [168]
NXT1 OT0VO6AY Definitive Altered Expression [168]
SUB1 OTK71JYU Definitive Altered Expression [168]
SULF1 OTJCNCO0 Definitive Biomarker [169]
------------------------------------------------------------------------------------
⏷ Show the Full List of 119 DOT(s)

References

1 Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma. Int J Dermatol. 2018 Oct;57(10):e90-e92.
2 Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells.Int J Mol Sci. 2017 Jul 5;18(7):1449. doi: 10.3390/ijms18071449.
3 Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.Nat Genet. 2011 Aug 7;43(9):875-8. doi: 10.1038/ng.907.
4 Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy.Am J Pathol. 2009 Nov;175(5):1824-30. doi: 10.2353/ajpath.2009.090155. Epub 2009 Oct 8.
5 The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.Tumour Biol. 2016 May;37(5):6275-83. doi: 10.1007/s13277-015-4509-5. Epub 2015 Nov 30.
6 Canine urothelial carcinoma: genomically aberrant and comparatively relevant.Chromosome Res. 2015 Jun;23(2):311-31. doi: 10.1007/s10577-015-9471-y. Epub 2015 Mar 18.
7 Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.Virchows Arch. 2010 Sep;457(3):319-28. doi: 10.1007/s00428-010-0943-3. Epub 2010 Jun 26.
8 Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.Nat Genet. 2013 Dec;45(12):1459-63. doi: 10.1038/ng.2798. Epub 2013 Oct 13.
9 In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.Oncol Rep. 2004 Oct;12(4):909-13.
10 BCL6 gene mutations in transitional cell carcinomas.J Int Med Res. 2007 Mar-Apr;35(2):224-30. doi: 10.1177/147323000703500206.
11 Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma.Toxicol Appl Pharmacol. 2008 Oct 15;232(2):203-9. doi: 10.1016/j.taap.2008.06.011. Epub 2008 Jul 1.
12 GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.Oncotarget. 2017 Apr 25;8(17):28826-28839. doi: 10.18632/oncotarget.16259.
13 BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway.Free Radic Biol Med. 2010 Sep 15;49(6):1072-81. doi: 10.1016/j.freeradbiomed.2010.06.023. Epub 2010 Jun 28.
14 Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.Virchows Arch. 2020 Apr;476(4):535-542. doi: 10.1007/s00428-019-02661-2. Epub 2019 Sep 2.
15 Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer.Proteomics. 2007 Nov;7(22):4192-202. doi: 10.1002/pmic.200700582.
16 Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.J Korean Med Sci. 2017 Aug;32(8):1327-1336. doi: 10.3346/jkms.2017.32.8.1327.
17 Identification of differently expressed genes in chemical carcinogen-induced rat bladder cancers.J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):220-6. doi: 10.1007/s11596-009-0217-y. Epub 2009 Apr 28.
18 Expression levels of transcription factors c-Fos and c-Jun and transmembrane protein HAb18G/CD147 in urothelial carcinoma of the bladder.Mol Med Rep. 2017 May;15(5):2991-3000. doi: 10.3892/mmr.2017.6411. Epub 2017 Mar 30.
19 Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer.Oncol Lett. 2017 Jul;14(1):999-1004. doi: 10.3892/ol.2017.6230. Epub 2017 May 23.
20 Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.PLoS One. 2012;7(3):e33615. doi: 10.1371/journal.pone.0033615. Epub 2012 Mar 16.
21 Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance.Tumour Biol. 2008;29(5):323-9. doi: 10.1159/000170879. Epub 2008 Nov 5.
22 Cyclin A overexpression in carcinoma of the renal pelvis and ureter including dysplasia: immunohistochemical findings in relation to prognosis.Clin Cancer Res. 1997 Aug;3(8):1399-404.
23 Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma.Cancer Genomics Proteomics. 2014 May-Jun;11(3):141-53.
24 Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas.Pathol Res Pract. 2005;201(12):803-8. doi: 10.1016/j.prp.2005.09.003. Epub 2005 Nov 3.
25 High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer.Virchows Arch. 2013 Nov;463(5):681-7. doi: 10.1007/s00428-013-1473-6. Epub 2013 Aug 31.
26 Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).Int J Urol. 1994 Jun;1(2):140-2. doi: 10.1111/j.1442-2042.1994.tb00023.x.
27 Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Br J Cancer. 2012 Jun 26;107(1):116-22. doi: 10.1038/bjc.2012.215. Epub 2012 May 17.
28 A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.Ann Oncol. 2017 Apr 1;28(4):798-803. doi: 10.1093/annonc/mdw675.
29 Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival.Future Oncol. 2019 Jun;15(17):2009-2018. doi: 10.2217/fon-2018-0748. Epub 2019 Apr 1.
30 Expression of Estrogen Receptor Beta Predicts Oncologic Outcome of pT3 Upper Urinary Tract Urothelial Carcinoma Better Than Aggressive Pathological Features.Sci Rep. 2016 Apr 7;6:24263. doi: 10.1038/srep24263.
31 The molecular signature for urothelial carcinoma of the upper urinary tract.J Urol. 2008 Mar;179(3):1155-9. doi: 10.1016/j.juro.2007.10.026.
32 ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.Sci Rep. 2019 Apr 5;9(1):5740. doi: 10.1038/s41598-018-36456-3.
33 Expression of GFR3 correlates with tumor progression and promotes cell metastasis in urothelial carcinoma.Minerva Urol Nefrol. 2018 Feb;70(1):79-86. doi: 10.23736/S0393-2249.17.02887-9. Epub 2017 Jun 23.
34 Expression and role of GPR87 in urothelial carcinoma of the bladder.Int J Mol Sci. 2013 Jun 10;14(6):12367-79. doi: 10.3390/ijms140612367.
35 Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant.J Urol. 2004 Aug;172(2):728-32. doi: 10.1097/01.ju.0000130942.40597.9d.
36 GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.Redox Rep. 2013;18(1):1-7. doi: 10.1179/1351000212Y.0000000031.
37 HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment.Curr Med Chem. 2017;24(37):4151-4165. doi: 10.2174/0929867324666170207142740.
38 HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.APMIS. 2016 Mar;124(3):188-93. doi: 10.1111/apm.12483. Epub 2015 Nov 20.
39 Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.Cancer Sci. 2017 Mar;108(3):331-337. doi: 10.1111/cas.13143.
40 The relationship of histamine H2 receptor-bearing suppressor cells with the growth and metastasis of FANFT-induced bladder cancer.J Surg Oncol. 1983 Sep;24(1):53-8. doi: 10.1002/jso.2930240113.
41 Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006 Dec;5(12):3032-41. doi: 10.1158/1535-7163.MCT-05-0474.
42 Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.Cancer Res. 1990 Feb 15;50(4):1071-4.
43 The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.Arch Toxicol. 2011 Oct;85(10):1209-18. doi: 10.1007/s00204-011-0671-8. Epub 2011 Feb 24.
44 IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.Medicine (Baltimore). 2019 Jul;98(27):e16009. doi: 10.1097/MD.0000000000016009.
45 INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract.J Surg Oncol. 2015 Mar 15;111(4):414-22. doi: 10.1002/jso.23836. Epub 2014 Dec 9.
46 Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.Mod Pathol. 2019 May;32(5):717-724. doi: 10.1038/s41379-018-0177-5. Epub 2018 Nov 15.
47 LASP-1, a novel urinary marker for detection of bladder cancer.Urol Oncol. 2013 Nov;31(8):1591-8. doi: 10.1016/j.urolonc.2012.02.002. Epub 2012 Apr 4.
48 Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study.Int J Cancer. 2002 Aug 20;100(6):702-5. doi: 10.1002/ijc.10540.
49 Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13.
50 Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.Genet Med. 2020 Apr;22(4):709-718. doi: 10.1038/s41436-019-0720-x. Epub 2019 Dec 17.
51 NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.Cancers (Basel). 2018 Sep 21;10(10):347. doi: 10.3390/cancers10100347.
52 Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.Cancer Biomark. 2019;25(2):151-160. doi: 10.3233/CBM-182020.
53 Targeting advanced urothelial carcinoma-developing strategies.Curr Opin Oncol. 2019 May;31(3):207-215. doi: 10.1097/CCO.0000000000000532.
54 The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma.Onco Targets Ther. 2019 Sep 24;12:7725-7735. doi: 10.2147/OTT.S222422. eCollection 2019.
55 The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus.Cancer Res. 2007 Oct 1;67(19):9229-37. doi: 10.1158/0008-5472.CAN-07-1333.
56 HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.PLoS One. 2012;7(11):e49341. doi: 10.1371/journal.pone.0049341. Epub 2012 Nov 7.
57 Prostate stem cell antigen is overexpressed in human transitional cell carcinoma.Cancer Res. 2001 Jun 15;61(12):4660-5.
58 Elevated prostaglandin E2 level via cPLA2--COX-2--mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats.Prostaglandins Leukot Essent Fatty Acids. 2006 May;74(5):309-15. doi: 10.1016/j.plefa.2006.02.005. Epub 2006 Apr 18.
59 Effects of DNMT and MEK inhibitors on the expression of RECK, MMP-9, -2, uPA and VEGF in response to arsenite stimulation in human uroepithelial cells.Toxicol Lett. 2011 Feb 25;201(1):62-71. doi: 10.1016/j.toxlet.2010.12.006. Epub 2010 Dec 15.
60 Aberrant -catenin expression in urothelial carcinomas in blackfoot disease-endemic areas.Kaohsiung J Med Sci. 2017 Jan;33(1):11-16. doi: 10.1016/j.kjms.2016.10.006. Epub 2016 Nov 4.
61 Toll-like receptor 6 and connective tissue growth factor are significantly upregulated in mitomycin-C-treated urothelial carcinoma cells under hydrostatic pressure stimulation.Genet Test Mol Biomarkers. 2014 Jun;18(6):410-6. doi: 10.1089/gtmb.2013.0443. Epub 2014 Apr 1.
62 Evaluation of thymosin 4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.Urol Oncol. 2012 Mar-Apr;30(2):167-76. doi: 10.1016/j.urolonc.2010.02.009. Epub 2010 Sep 22.
63 Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience.Clin Chem Lab Med. 2007;45(7):862-6. doi: 10.1515/CCLM.2007.133.
64 Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.Eur Urol. 2008 Sep;54(3):612-20. doi: 10.1016/j.eururo.2007.10.016. Epub 2007 Oct 16.
65 Effects of calcitriol, seocalcitol, and medium-chain triglyceride on a canine transitional cell carcinoma cell line.Anticancer Res. 2005 Jul-Aug;25(4):2689-96.
66 DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.Oncotarget. 2016 Nov 29;7(48):78918-78931. doi: 10.18632/oncotarget.12912.
67 PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.Mol Cancer. 2013 Nov 23;12(1):148. doi: 10.1186/1476-4598-12-148.
68 Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.
69 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma.Toxicol Lett. 2013 Jan 10;216(1):16-22. doi: 10.1016/j.toxlet.2012.11.002. Epub 2012 Nov 8.
70 Gene polymorphisms of glutathione S-transferase omega 1 and 2, urinary arsenic methylation profile and urothelial carcinoma.Sci Total Environ. 2011 Jan 1;409(3):465-70. doi: 10.1016/j.scitotenv.2010.10.053. Epub 2010 Nov 21.
71 Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation.Cancer Res. 1998 Mar 15;58(6):1291-7.
72 EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.Tumour Biol. 2007;28(3):151-7. doi: 10.1159/000103380. Epub 2007 Jun 1.
73 FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.Virchows Arch. 2017 Sep;471(3):337-345. doi: 10.1007/s00428-017-2190-3. Epub 2017 Jul 18.
74 The evolving genomic landscape of urothelial carcinoma.Nat Rev Urol. 2017 Feb 7;14(4):215-229. doi: 10.1038/nrurol.2017.11. Online ahead of print.
75 Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder.Pathol Oncol Res. 2020 Jan;26(1):411-418. doi: 10.1007/s12253-018-0524-3. Epub 2018 Oct 31.
76 HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?.Eur J Cancer. 2004 Jan;40(1):56-63. doi: 10.1016/j.ejca.2003.08.027.
77 Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study.Urol Oncol. 2011 Mar-Apr;29(2):150-6. doi: 10.1016/j.urolonc.2009.01.003. Epub 2009 Mar 9.
78 MCL1 and DEDD Promote Urothelial Carcinoma Progression.Mol Cancer Res. 2019 Jun;17(6):1294-1304. doi: 10.1158/1541-7786.MCR-18-0963. Epub 2019 Feb 18.
79 Primary small cell carcinoma of the ureter: Case report and review of the literature.Medicine (Baltimore). 2018 Jun;97(24):e11113. doi: 10.1097/MD.0000000000011113.
80 Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.
81 Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma.Int J Mol Sci. 2019 Apr 3;20(7):1653. doi: 10.3390/ijms20071653.
82 Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.BMC Cancer. 2015 Nov 23;15:927. doi: 10.1186/s12885-015-1930-5.
83 High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas.Urol Oncol. 2019 Apr;37(4):293.e11-293.e24. doi: 10.1016/j.urolonc.2018.12.009. Epub 2018 Dec 27.
84 Blood group ABH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas.Int J Cancer. 1989 May 15;43(5):774-80. doi: 10.1002/ijc.2910430505.
85 ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression.Cancer Sci. 2013 Mar;104(3):321-7. doi: 10.1111/cas.12089. Epub 2013 Feb 14.
86 ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals.Clin Cancer Res. 2012 Oct 1;18(19):5247-55. doi: 10.1158/1078-0432.CCR-12-0955. Epub 2012 Jul 31.
87 Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.Eur Urol. 2003 Dec;44(6):737-41. doi: 10.1016/s0302-2838(03)00383-x.
88 Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21.
89 Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.Cancer Cytopathol. 2019 Sep;127(9):578-585. doi: 10.1002/cncy.22167. Epub 2019 Aug 6.
90 Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?.Clin Genitourin Cancer. 2019 Dec;17(6):e1122-e1128. doi: 10.1016/j.clgc.2019.07.016. Epub 2019 Aug 5.
91 A novel member of the glycosyltransferase family, beta 3 Gn-T2, highly downregulated in invasive human bladder transitional cell carcinomas.Mol Carcinog. 2001 Oct;32(2):61-72. doi: 10.1002/mc.1065.
92 Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC).Genes Chromosomes Cancer. 2009 Aug;48(8):694-710. doi: 10.1002/gcc.20672.
93 Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.J Pathol. 2008 Jul;215(3):263-72. doi: 10.1002/path.2353.
94 Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.Int J Mol Med. 2006 Oct;18(4):547-57.
95 Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway.Cancer Sci. 2017 Nov;108(11):2166-2175. doi: 10.1111/cas.13383. Epub 2017 Sep 25.
96 Establishment and characterization of two human bladder cancer cell lines.Hum Cell. 1996 Mar;9(1):49-56.
97 Methylation profiling of urothelial carcinoma in bladder biopsy and urine.Acta Cytol. 2006 Sep-Oct;50(5):499-506. doi: 10.1159/000326003.
98 The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.J Mol Diagn. 2000 Aug;2(3):116-23. doi: 10.1016/S1525-1578(10)60625-3.
99 MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.J Cell Biochem. 2017 Jun;118(6):1563-1573. doi: 10.1002/jcb.25818. Epub 2016 Dec 20.
100 Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.Immunobiology. 2015 Jan;220(1):103-8. doi: 10.1016/j.imbio.2014.08.014. Epub 2014 Aug 21.
101 The transcripts of SFRP1,CEP63 and EIF4G2 genes are frequently downregulated in transitional cell carcinomas of the bladder.Oncology. 2005;69(6):445-54. doi: 10.1159/000090984. Epub 2006 Jan 12.
102 Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.Eur Urol. 2005 Jan;47(1):58-63. doi: 10.1016/j.eururo.2004.07.012.
103 Increased SKP2 and CKS1 gene expression contributes to the progression of human urothelial carcinoma.J Urol. 2007 Jul;178(1):301-7. doi: 10.1016/j.juro.2007.03.002. Epub 2007 May 17.
104 MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells.Int J Mol Sci. 2017 Aug 22;18(8):1826. doi: 10.3390/ijms18081826.
105 The prognostic value of sarcopenia in patients with surgically treated urothelial carcinoma: A systematic review and meta-analysis.Eur J Surg Oncol. 2019 May;45(5):747-754. doi: 10.1016/j.ejso.2019.03.003. Epub 2019 Mar 7.
106 Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells.Cancer Res. 2001 Mar 1;61(5):2261-6.
107 CSTF2-Induced Shortening of the RAC1 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder.Cancer Res. 2018 Oct 15;78(20):5848-5862. doi: 10.1158/0008-5472.CAN-18-0822. Epub 2018 Aug 24.
108 Alpha-T-catenin (CTNNA3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder.Genes Chromosomes Cancer. 2007 Jun;46(6):587-93. doi: 10.1002/gcc.20443.
109 Expression of CUL1 correlates with tumour-grade and recurrence in urothelial carcinoma.ANZ J Surg. 2017 Jul;87(7-8):624-629. doi: 10.1111/ans.13438. Epub 2016 Jun 16.
110 Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.Virchows Arch. 2016 Jun;468(6):733-40. doi: 10.1007/s00428-016-1924-y. Epub 2016 Mar 22.
111 Low expression of DAB2IP predicts an unfavorable prognosis in human bladder carcinoma.Onco Targets Ther. 2017 Nov 29;10:5719-5726. doi: 10.2147/OTT.S146952. eCollection 2017.
112 Prospective validation of DACH2 as a novel biomarker for prediction of metastasis and prognosis in muscle-invasive urothelial carcinoma of the bladder.Biochem Biophys Res Commun. 2015 Apr 10;459(3):416-23. doi: 10.1016/j.bbrc.2015.02.119. Epub 2015 Mar 2.
113 Relationships among MTHFR a1298c gene polymorphisms and methylation status of Dact1 gene in transitional cell carcinomas.Asian Pac J Cancer Prev. 2012;13(10):5069-74. doi: 10.7314/apjcp.2012.13.10.5069.
114 Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer.Mol Med Rep. 2012 Mar;5(3):695-9. doi: 10.3892/mmr.2011.711. Epub 2011 Dec 14.
115 Prognostic and predictive value of HURP in nonsmall cell lung cancer.Oncol Rep. 2018 Apr;39(4):1682-1692. doi: 10.3892/or.2018.6280. Epub 2018 Feb 26.
116 Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.Clin Cancer Res. 2006 Jan 15;12(2):353-60. doi: 10.1158/1078-0432.CCR-05-1505.
117 Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells.Toxicol Lett. 2013 Jul 4;220(2):118-25. doi: 10.1016/j.toxlet.2013.04.007. Epub 2013 Apr 22.
118 Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract.Am J Pathol. 2013 Sep;183(3):709-19. doi: 10.1016/j.ajpath.2013.05.015. Epub 2013 Jul 6.
119 EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer.Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):199-211. doi: 10.1016/j.bbcan.2017.04.004. Epub 2017 Apr 10.
120 The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis.J Natl Cancer Inst. 2002 Sep 18;94(18):1381-95. doi: 10.1093/jnci/94.18.1381.
121 On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer.Nat Rev Urol. 2017 Feb;14(2):98-106. doi: 10.1038/nrurol.2016.239. Epub 2016 Nov 29.
122 Gab1 is essential for membrane translocation, activity and integrity of mTORCs after EGF stimulation in urothelial cell carcinoma.Oncotarget. 2015 Jan 30;6(3):1478-89. doi: 10.18632/oncotarget.2756.
123 Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.Jpn J Clin Oncol. 2015 Nov;45(11):1055-63. doi: 10.1093/jjco/hyv132. Epub 2015 Sep 14.
124 GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis.Oncotarget. 2018 Mar 23;9(22):15847-15859. doi: 10.18632/oncotarget.24627. eCollection 2018 Mar 23.
125 HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder.Tumour Biol. 2015 Jul;36(7):5441-50. doi: 10.1007/s13277-015-3210-z. Epub 2015 May 2.
126 Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.World J Urol. 2010 Aug;28(4):473-8. doi: 10.1007/s00345-010-0573-z. Epub 2010 Jul 1.
127 Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.Am J Pathol. 2005 May;166(5):1533-9. doi: 10.1016/S0002-9440(10)62369-3.
128 Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-B-mediated MMP-9 expression inducing the MAPK pathway.Cell Signal. 2012 Sep;24(9):1734-42. doi: 10.1016/j.cellsig.2012.04.013. Epub 2012 Apr 25.
129 Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure.Environ Res. 2014 Jan;128:57-63. doi: 10.1016/j.envres.2013.10.006. Epub 2013 Nov 22.
130 Contingencies of UTX/KDM6A Action in Urothelial Carcinoma.Cancers (Basel). 2019 Apr 4;11(4):481. doi: 10.3390/cancers11040481.
131 High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.BMC Cancer. 2015 May 9;15:380. doi: 10.1186/s12885-015-1369-8.
132 Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.Int J Mol Sci. 2019 Jan 29;20(3):570. doi: 10.3390/ijms20030570.
133 Ureteroscopic Management of Large ? cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience.Urology. 2018 Nov;121:66-73. doi: 10.1016/j.urology.2018.05.042. Epub 2018 Jun 30.
134 LGALS4 as a Prognostic Factor in Urothelial Carcinoma of Bladder Affects Cell Functions.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819876601. doi: 10.1177/1533033819876601.
135 Immunocytochemical demonstration of p21ras in normal and transitional cell carcinoma urothelium.J Pathol. 1988 Sep;156(1):59-65. doi: 10.1002/path.1711560112.
136 FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.Am J Pathol. 2002 Apr;160(4):1345-52. doi: 10.1016/S0002-9440(10)62561-8.
137 Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling.Onco Targets Ther. 2018 Jun 6;11:3323-3333. doi: 10.2147/OTT.S157025. eCollection 2018.
138 Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.Histopathology. 2017 Jan;70(2):281-289. doi: 10.1111/his.13063. Epub 2016 Oct 28.
139 Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells.Mutat Res. 2007 Feb 3;615(1-2):75-86. doi: 10.1016/j.mrfmmm.2006.10.003. Epub 2006 Nov 28.
140 MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.Oncotarget. 2016 Nov 22;7(47):77777-77792. doi: 10.18632/oncotarget.12795.
141 Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor.Urology. 2003 Jul;62(1):182-6. doi: 10.1016/s0090-4295(03)00238-3.
142 Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy.Urol Oncol. 2017 Dec;35(12):674.e19-674.e24. doi: 10.1016/j.urolonc.2017.08.004. Epub 2017 Sep 6.
143 Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.Br J Cancer. 2013 Apr 2;108(6):1368-77. doi: 10.1038/bjc.2013.104.
144 Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.Cancer Biomark. 2017;18(4):381-387. doi: 10.3233/CBM-160261.
145 Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells.Mol Cancer Res. 2008 Jul;6(7):1154-68. doi: 10.1158/1541-7786.MCR-07-2168.
146 A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.J Urol. 2012 Sep;188(3):741-7. doi: 10.1016/j.juro.2012.05.003. Epub 2012 Jul 19.
147 PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target.PLoS One. 2019 Oct 22;14(10):e0224085. doi: 10.1371/journal.pone.0224085. eCollection 2019.
148 AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.Cancer Genet Cytogenet. 2009 May;191(1):34-7. doi: 10.1016/j.cancergencyto.2009.01.009.
149 Mutational analysis of Noxa gene in human cancers.APMIS. 2003 Jun;111(6):599-604. doi: 10.1034/j.1600-0463.2003.1110602.x.
150 Loss of periplakin expression is associated with the tumorigenesis of colorectal carcinoma.Biomed Pharmacother. 2017 Mar;87:366-374. doi: 10.1016/j.biopha.2016.12.103. Epub 2017 Jan 6.
151 KIAA1096, a gene on chromosome 1q, is amplified and overexpressed in bladder cancer.DNA Cell Biol. 2002 Oct;21(10):707-15. doi: 10.1089/104454902760599681.
152 Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.J Cancer Res Clin Oncol. 2016 May;142(5):937-47. doi: 10.1007/s00432-015-2107-y. Epub 2016 Jan 8.
153 Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.Br J Cancer. 2016 Feb 2;114(3):305-13. doi: 10.1038/bjc.2015.444. Epub 2016 Jan 7.
154 Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.Pathol Oncol Res. 2014 Jul;20(3):549-56. doi: 10.1007/s12253-013-9727-9. Epub 2014 Jan 11.
155 Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.Sci Rep. 2016 Feb 12;6:20894. doi: 10.1038/srep20894.
156 Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract.Pathobiology. 2004;71(2):103-6. doi: 10.1159/000074424.
157 Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis.Actas Urol Esp. 2014 Oct;38(8):506-14. doi: 10.1016/j.acuro.2014.02.015. Epub 2014 Apr 3.
158 SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.Clin Cancer Res. 2015 Dec 15;21(24):5601-11. doi: 10.1158/1078-0432.CCR-14-3308. Epub 2015 Aug 18.
159 Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.Neoplasia. 2013 Jul;15(7):749-60. doi: 10.1593/neo.121956.
160 Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma.Am J Clin Pathol. 2013 Jun;139(6):765-70. doi: 10.1309/AJCPBSLP8XHSWLOW.
161 TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration.Int J Mol Sci. 2019 Sep 11;20(18):4483. doi: 10.3390/ijms20184483.
162 Human TLR gene family members are differentially expressed in patients with urothelial carcinoma of the bladder.Urol Oncol. 2017 Dec;35(12):674.e11-674.e17. doi: 10.1016/j.urolonc.2017.07.029. Epub 2017 Aug 24.
163 Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder.Urol Oncol. 2017 Apr;35(4):152.e7-152.e12. doi: 10.1016/j.urolonc.2016.10.014. Epub 2017 Feb 1.
164 Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder.Int J Cancer. 2004 Jun 20;110(3):368-73. doi: 10.1002/ijc.20151.
165 A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.World J Urol. 2018 Nov;36(11):1719-1725. doi: 10.1007/s00345-018-2334-3. Epub 2018 May 16.
166 TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.Lab Invest. 2019 Nov;99(11):1702-1713. doi: 10.1038/s41374-019-0285-y. Epub 2019 Jul 1.
167 Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma.Oncol Rep. 2014 Aug;32(2):748-54. doi: 10.3892/or.2014.3221. Epub 2014 May 29.
168 Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.Clin Biochem. 2004 Dec;37(12):1098-104. doi: 10.1016/j.clinbiochem.2004.09.006.
169 Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.Oncotarget. 2017 Jul 18;8(29):47216-47229. doi: 10.18632/oncotarget.17590.